Canada markets open in 37 minutes
  • S&P/TSX

    19,235.09
    -135.91 (-0.70%)
     
  • S&P 500

    3,783.28
    -7.65 (-0.20%)
     
  • DOW

    30,273.87
    -42.43 (-0.14%)
     
  • CAD/USD

    0.7316
    -0.0030 (-0.40%)
     
  • CRUDE OIL

    87.84
    +0.08 (+0.09%)
     
  • BTC-CAD

    27,662.54
    +126.81 (+0.46%)
     
  • CMC Crypto 200

    460.48
    +2.07 (+0.45%)
     
  • GOLD FUTURES

    1,724.70
    +3.90 (+0.23%)
     
  • RUSSELL 2000

    1,762.69
    -13.08 (-0.74%)
     
  • 10-Yr Bond

    3.7510
    -0.0080 (-0.21%)
     
  • NASDAQ futures

    11,646.25
    +22.50 (+0.19%)
     
  • VOLATILITY

    28.85
    -0.22 (-0.76%)
     
  • FTSE

    6,995.98
    -56.64 (-0.80%)
     
  • NIKKEI 225

    27,311.30
    +190.80 (+0.70%)
     
  • CAD/EUR

    0.7412
    -0.0015 (-0.20%)
     

Iveric Bio to Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

·1 min read

PARSIPPANY, N.J., August 10, 2022--(BUSINESS WIRE)--IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will participate in a panel discussion titled, "Differentiation in Emerging Treatments for GA dAMD -- Perspectives From ISEE," at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on Wednesday, August 17, 2022, at 9:00 a.m. Eastern Time.

Investors and the general public are invited to access the live webcast of the panel discussion on the Investor / Events & Presentations section of the Iveric Bio website at www.ivericbio.com. An archived replay of the on-demand presentation will be available on the Company’s website immediately following the conference and for at least 30 days thereafter.

About Iveric Bio
Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.

Forward-looking Statements

Any statements in this press release or made during the presentation referenced herein about Iveric Bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those described in the "Risk Factors" section of public filings made by Iveric Bio with the U.S. Securities and Exchange Commission. Any forward-looking statements represent Iveric Bio’s views only as of the date of this press release or the presentation, as applicable. Iveric Bio anticipates that subsequent events and developments may cause its views to change. While Iveric Bio may elect to update these forward-looking statements at some point in the future, Iveric Bio specifically disclaims any obligation to do so unless required by law.

ISEE-G

View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005782/en/

Contacts

Investor Contact:
Kathy Galante
Senior Vice President, Investor Relations
kathy.galante@ivericbio.com

or

Media Contact:
Jeannie Neufeld
Senior Director, Public Relations and Communications
jeannie.neufeld@ivericbio.com